OncoMatch/Clinical Trials/NCT04685616
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Is NCT04685616 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for hodgkin lymphoma.
Treatment: Doxorubicin · Bleomycin · Brentuximab vedotin · Vinblastine · Dacarbazine · Haematopoietic growth factor — RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any treatment for hodgkin lymphoma
Exception: short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days
Lab requirements
Blood counts
Adequate bone marrow function with neutrophils ≥1.0x10^9/l and platelets ≥100x10^9/l; Haemoglobin ≥8g/dL
Kidney function
Creatinine clearance (measured or calculated) >40ml/min
Liver function
Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome; ALT or AST < 2 x upper limit of normal
Cardiac function
Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
Creatinine clearance (measured or calculated >40ml/min; Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome; ALT or AST < 2 x upper limit of normal; Adequate bone marrow function with neutrophils ≥1.0x10^9/l and platelets ≥100x10^9/l; Haemoglobin ≥8g/dL; Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University - (Stanford Cancer Institute) · Stanford, California
- University of Miami School of Medicine · Miami, Florida
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify